Table 2:

ADC (×10−3 mm2/s) and FA measurements in patients with DIBSG at various stages of the disease, in controls, and in untreated medulloblastoma and pilocytic astrocytoma

DIBSGaADCmeanFAmeanADCminFAminADCmaxFAmax
Baseline1.14 ± 0.180.24 ± 0.040.96 ± 0.170.20 ± 0.051.29 ± 0.220.30 ± 0.05
Early post-RTb0.91 ± 0.10c0.32 ± 0.08d0.77 ± 0.09d0.25 ± 0.071.03 ± 0.12c0.42 ± 0.09d
Late post-RTe0.91 ± 0.10c0.29 ± 0.050.84 ± 0.080.24 ± 0.050.98 ± 0.1c0.34 ± 0.08
Controls0.75 ± 0.06f0.43 ± 0.02f0.69 ± 0.04f0.33 ± 0.06f0.83 ± 0.11f0.50 ± 0.02f
Medulloblastoma0.56 ± 0.05f0.24 ± 0.10n.d.n.d.n.d.n.d.
Pilocytic astrocytoma1.14 ± 0.270.17 ± 0.05dn.d.n.d.n.d.n.d.
  • a ADC decreased and FA increased significantly between baseline and the early post-RT period. Thereafter, no significant differences were observed. At baseline, DIBSG had significantly higher ADC than the brain stem of controls and medulloblastoma. Also, baseline FA was lower than the FA of brain stem of controls and higher than FA of pilocytic astrocytoma.

  • b From 11 scans performed within 3 months of completion of RT (3.3 ± 1.7 months after initial diagnosis).

  • c P < .005.

  • d P < .05.

  • e From 13 scans performed >3 months after completion of RT (9.7 ± 3.6 months after initial diagnosis).

  • f P < .001 versus baseline DIBSG, unpaired t test.